Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PW Medtech GroupFRA:PWE 57 PB Ratio is 0.32 as of Jul. 17, 2026, which is 14% below its 10-year median of 0.37. GuruFocus rates FRA:PWE with a GF Score™ of 57/100 and a GF Value™ of €0.14 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 787 Medical Devices & Instruments companies, PW Medtech Group ranks better than 95.68% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-17), PW Medtech Group's share price is €0.103. PW Medtech Group's Book Value per Share for the quarter that ended in Dec. 2025 was €0.33. Hence, PW Medtech Group's PB Ratio of today is 0.32.
Good Sign:
PW Medtech Group Ltd stock PB Ratio (=0.36) is close to 1-year low of 0.34.
The historical rank and industry rank for PW Medtech Group's PB Ratio or its related term are showing as below:
FRA:PWE'
s PB Ratio Range Over the Past 10 Years
Min: 0.13 Med: 0.37 Max: 1.57
Current: 0.36
During the past 13 years, PW Medtech Group's highest PB Ratio was 1.57. The lowest was 0.13. And the median was 0.37.
FRA:PWE's PB Ratio is ranked better than 95.68% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs FRA:PWE: 0.36
During the past 12 months, PW Medtech Group's average Book Value Per Share Growth Rate was 4.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -4.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 5.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of PW Medtech Group was 84.70% per year. The lowest was -9.90% per year. And the median was 4.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
PW Medtech Group PB Ratio Related Terms
PW Medtech Group PB Ratio Historical Data
* Premium members only.
The historical data trend for PW Medtech Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, PW Medtech Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PW Medtech Group PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PW Medtech Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where PW Medtech Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
PW Medtech Group (FRA:PWE) has a PB Ratio of 0.32 as of Jul. 17, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on PW Medtech Group and its competitors. This is 14% below median its historical median of 0.37. Over the past decade, PW Medtech Group's PB Ratio has ranged from 0.13 to 1.57. According to the industry distribution chart, PW Medtech Group ranks #34 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 4.3%.
Is PW Medtech Group's PB Ratio too high?
PW Medtech Group's current PB Ratio of 0.32 is 14% below median its 10-year median of 0.37. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 1.57. The Medical Devices & Instruments industry median PB Ratio is 2.05. PW Medtech Group's value of 0.32 is 84.4% below this industry median. Based on the distribution chart, PW Medtech Group ranks #34 out of 787 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, PW Medtech Group has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PW Medtech Group's PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PW Medtech Group ranks #34 out of 787 companies for PB Ratio. This places PW Medtech Group in the top 4% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.05. PW Medtech Group's value of 0.32 is 84.4% below this benchmark. Historically, PW Medtech Group's own PB Ratio has ranged from 0.13 to 1.57 over the past decade. While the company's 10-year median is 0.37 vs. the industry median of 2.05, PW Medtech Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PW Medtech Group's current PB Ratio of 0.32 is 84.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on PW Medtech Group and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PW Medtech Group's current PB Ratio is 0.32, which is 14% below median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PW Medtech Group stock overvalued right now?
Based on GuruFocus' analysis, PW Medtech Group (FRA:PWE) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.14, compared to a current price of €0.10 — trading 26.4% below its estimated fair value. The current PB Ratio is 0.32, which is 14% below median its 10-year median of 0.37 and 84.4% below the Medical Devices & Instruments industry median of 2.05. PW Medtech Group's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For PW Medtech Group (FRA:PWE), the current PB Ratio is 0.32 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PW Medtech Group (FRA:PWE) Overvalued in 2026?
Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued.
The current stock price of €0.10 is trading 26.4% below its estimated GF Value™ of €0.14.
GuruFocus considers PW Medtech Group to be Modestly Undervalued.
Key valuation signals for FRA:PWE:
PB Ratio: 0.32 (14% below median its 10-year median of 0.37)
GF Value™: €0.14 vs. price of €0.10 (26.4% below fair value)
Industry Position: 84.4% below the Medical Devices & Instruments median (#34 of 787)
No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
57GF Score
Get the complete analysis for FRA:PWE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PWE has been successfully added to your 
